Bulletin "Veterinary biotechnology"

Veterynarna biotehnologija – Veterinary biotechnology, 2018, 32(1), 478-483 [in Ukrainian]. https://doi.org/10.31073/vet_biotech32(1)-64

PINCHUK N.G.e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., GOLOVKO A.N., ZUBCHUK R.O.

State Scientific Control Institute of Biotechnology and strains (DNKIBSHM)

WORLD EXPERIENCE OF THE USE OF AUTOGENIC VACCINES FOR PREVENTION OF BACTERIAL DISEASES OF ANIMALS AND THEIR PROBLEMS APPLICATION IN UKRAINE

Introduction. Actual issues for today are active genetic transformation of microorganisms by increasing virulence, antigenic variability of pathogens of many known infectious diseases. Therefore, the use of inactivated autogenic vaccines is becoming particularly relevant in today's conditions. It is the homology of the vaccine and the field microorganisms that makes the biopreparat most effective in a particular economy.

The goal of the work it was conducted an analysis of international recommendations on the manufacture, control and use of inactivated autogenic vaccines and the study of the problem of their use in Ukraine.

Materials and methods. The International recommendations for the manufacture, control and use of inactivated autogenic vaccines were analyzed and the draft "Procedure for the manufacture and use of veterinary autogenic vaccines", developed by the State Scientific Control Institute of Biotechnology and Strains of Microorganisms, submitted for consideration and approval to the State Veterinary and Phytosanitary Service of Ukraine.

Results of research and discussion. The requirements of this project are absolutely consistent with international recommendations, but the long process of consideration and approval makes it impossible to use inactivated autogenic vaccines in Ukraine, which in turn leads to an increase in the use of antibiotics in most cases of bacterial etiology of any localization, while in other countries, the problem is solved by the use of autogenous vaccines and animal health, while avoiding excessive use of antibiotics.

Conclusions and prospects for further research. The absence of current domestic requirements for the manufacture, control and use of inactivated autogenic vaccines, harmonized with international standards makes it impossible to use these vaccines in Ukraine, which in turn leads to an increase in the use of antibiotics in most cases of bacterial etiology of any localization and increasing the resistance of cultures of bacteria circulating in Ukraine.

Keywords: inactivated autogenic vaccines, animals, European Economic Area.

REFERENCES

  1. Recommendations for the manufacture, control and use of inactivated autogenous veterinary vaccines within the EEA (2017). www.hma.eu. Retrieved from http://www.hma.eu/fileadmin/dateien/Veterinary_medicines/CMDv_Website/Procedural_guidance/Miscellaneous/Recommendations_manufacture_control_use_inact_autogenous_vaccines.pdf.
  2. Gesetz zur Vorbeugung vor und Bekämpfung von Tierseuchen [Law for the prevention and control of animal diseases]. (May 27, 2013). Bundesgesetzblatt Jahrgang – Federal Law Gazette. [in Duetsch].
  3. Verordnung über Sera, Impfstoffe, und Antigene nach dem Tierseuchengesetz [Ordinance on Sera, Vaccines, and Antigens According to the Animal Epidemic Act]. (October 24, 2006). Bundesgesetzblatt Jahrgang – Federal Law Gazette. [in Duetsch].
  4. Ausführungshinweise zur Verordnung über Sera, Impfstoffe und Antigene nach dem Tierseuchengesetz (Tierimpfstoff-Verordnung) [Implementation notes to the Ordinance on Sera, Vaccines and Antigens according to the Animal Epidemic Act (Animal Vaccine Ordinance)]. (2006). www.gesetze-im-internet.de. Retrieved from https://www.gesetze-im-internet.de/tierimpfstv_2006/BJNR235500006.html [in Duetsch].
  5. Jungback, C. (Eds.). (2004). Consideration of Alternative Licensing Procedures for Vaccines for Minor Species, Minor Indications and Autogenous. Autologous Products. Basel: Karger.
  6. Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (2003). www.ema.europa.eu. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf.

Download full text in PDF